Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

By afschroeder • March 14, 2026

Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot GE, Brinson C, Buchbinder S, Molina JM, Gravett RM, Brock JB, Ramgopal MN, Rosengren AL, Ofotokun I, Valdez Madruga J, Liegeon G, Panchia R, Supparatpinyo K, Avihingsanon A, Creticos C, Swaminathan S, Doblecki-Lewis S, Rodriguez J, Siegel M, Oka S, Puthanakit T, Grinsztejn B, Sanders EJ, Lama JR, Lombaard J, Ndlovu N, Hwang P, Du J, Jackson B, Homony B, Evans B, Sklar P, Robertson MN, Plank RM. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026 Mar 14:ciag171. doi: 10.1093/cid/ciag171. Epub ahead of print. PMID: 41830344.

Tags: cisgender men, HIV-1 prevention, Infectious Diseases, islatravir, PrEP, Publications, Transgender women

Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIV

Hoffman R, Brummel S, Pinilla M, Malonga G, Chinula L, Stranix-Chibanda L, Machado ES, Naik S, Rathore MH, Pilotto J, Masheto G, Stringer JSA, Shapiro[...]

HIVST in the presence of a partner among fishermen in Western Kenya: A qualitative stud

Abade P, Olugo P, Gutin SA, Nishimura H, Lewis-Kulzer J, Thorp M, Ayieko B, Oluoch L, Angawa D, Camlin CS, Kwena ZA. HIVST in the[...]

Inhibition of Candida albicans yeast-to-hypha transition and virulence by cyclic dipeptides derived from probiotic Aeromonas veronii V03

Sekar J, Parasuraman G, Shanmugam A, Dharumadurai D, Dileep Kumar BS, Natesan S. Inhibition of Candida albicans yeast-to-hypha transition and virulence by cyclic dipeptides derived[...]